Hedera Dx
Hedera Dx was created in 2021 with the mission to give access to liquid biopsy technologies to patients at risk of or already suffering from cancer.
Hedera Dx has raised €29M across 2 funding rounds from 10 investors, most recently a Series A round in May 2025. Based in Lausanne, Switzerland; active in Healthtech. Data as of 28 Oct 2026.
Lausanne, Switzerlandwww.hederadx.com ↗
Total raised
€29M
€29,000,000
Funding rounds
2
Investors
10
distinct backers
Active since
2022-09
latest 2025-05
Funding by year
EUR raised per yearHedera Dx — funding by year — interactive chart.
Data table
| Hedera Dx — funding by year | |
|---|---|
| 2022 | €14M |
| 2025 | €15M |
Signals
High confidenceRaise-next likelihood63
base rate 44% for Series A
- ▲ In typical raise window
- ▼ Low backer re-investment
Exit likelihood18
base rate 11% (2+ rounds)
- ▲ Recently backed by strong-exit-track investors
Timing: in window vs cohort gap · momentum flat. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-05-27 | Series A | €15M | Eyrir Invest,Helsana HealthInvest,Inventure,Tesi,Top Harvest Capital,Vsquared Ventures | View deal → |
| 2022-09-21 | Other | €14M | Air Street Capital,Adam Ghobarah,Amino Collective,GRIDS Capital,Inventure | View deal → |
Investors
10Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Climeworks€919MSwitzerland · Cleantech
Global coverage: FundingData